Key Takeaways
- Clinical Bottom Line
- This is no longer just a cannulation leaderboard
- What the updated indicators actually changed
- Why 90 percent still matters, but should not be weaponized
Clinical Bottom Line
| 2026 ERCP quality indicator | Current target |
|---|---|
| Accepted indication documented | ≥98% |
| Deep cannulation of the duct of interest in native papillae | ≥90% |
| Successful extraction of extrahepatic bile duct stones in normal anatomy | ≥90% |
| Rectal indomethacin or diclofenac in patients with intact papilla | ≥90% |
| Use or nonuse of prophylactic pancreatic stent documented and tracked in high-risk cases | ≥98% |
| Unplanned hospital visit within 30 days | <15% |
This is no longer just a cannulation leaderboard
ERCP quality is easy to reduce to one technical statistic and then overinterpret. Deep biliary cannulation success still matters. It remains one of the most important intraprocedural benchmarks. But the 2026 multi-society update is much broader than “good ERCP doctors cannulate at least 90%.”
The new ACG and ASGE framework proposes 13 quality indicators across preprocedure, intraprocedure, and postprocedure care. That means accepted indication, informed consent, antibiotics when appropriate, duct access, stone extraction success, rectal NSAIDs, pancreatic stent documentation in high-risk cases, and 30-day downstream outcomes all belong on the dashboard.
What the updated indicators actually changed
The headline number for deep cannulation of the duct of interest in native papillae remains 90% or greater. That part did not soften. What did change is the surrounding framework.
- Rectal NSAIDs are now a priority metric in all patients with an intact papilla, not just a nice extra for selected cases.
- Stone extraction quality now expects capability beyond tiny stones. The 2026 update removed the old less-than-10-mm comfort zone and expects same-session advanced extraction capability for extrahepatic bile duct stones in normal anatomy.
- Thirty-day downstream events now matter explicitly. Unplanned hospitalization and unplanned biliary intervention are formal quality outcomes, not just bad-luck footnotes.
Why 90 percent still matters, but should not be weaponized
The new guideline is explicit that these indicators are intended for quality improvement, not as blunt tools for credentialing or reimbursement. That distinction matters because a number can become dangerous when it is chased without context.
The ACG commentary accompanying the update makes the caution clear: rigid adherence to performance targets can push operators toward overly aggressive maneuvers that increase risk. That is especially relevant in difficult cannulation, where repeated traumatic attempts can raise PEP risk while the operator is still pretending the case is “standard.”
Difficult cannulation needs an objective clock
The 2025 WEO guideline is useful here because it defines difficult biliary cannulation in operational terms:
- more than 10 minutes after visualization of the papilla,
- more than 5 cannulation attempts, or
- at least 2 unintended pancreatic duct cannulations or contrast opacifications.
That objective definition is more helpful than vague language about “a tough papilla.” It gives units a cleaner trigger for escalating strategy and a fairer way to interpret cannulation statistics.
Your quality dashboard should include downstream harm
If a unit celebrates cannulation success but does not reliably track post-ERCP pancreatitis, hemorrhage, cholangitis, unplanned hospital visits, and unplanned biliary reinterventions, the quality program is incomplete.
The 2026 update makes that impossible to ignore. High-quality ERCP now means the procedure was indicated, technically successful, prophylaxis-conscious, and followed by outcome tracking that captures what happened after the fluoroscopy turned off.
A practical unit dashboard for 2026
| Domain | What to measure |
|---|---|
| Preprocedure | Accepted indication documented, ERCP-specific consent documented, antibiotics used for the right indications. |
| Intraprocedure | Deep cannulation success in native papillae, stone extraction success, radiation exposure documentation, universal rectal NSAIDs in intact papillae, and pancreatic stent documentation in high-risk cases. |
| Postprocedure | Unplanned hospital visit within 30 days, unplanned biliary intervention within 30 days, and consistent tracking of PEP, clinically significant bleeding, and cholangitis. |
What not to do in 2026
- Do not present one cannulation percentage without defining the denominator and difficulty mix.
- Do not chase a benchmark with repeated traumatic attempts that ignore an objective difficult-cannulation threshold.
- Do not call a case a quality success if prophylaxis and 30-day outcomes are not being measured.
- Do not pretend EUS-guided salvage turns an ERCP failure into a cannulation success for quality reporting.
Selected references
- Quality Indicators for ERCP. Am J Gastroenterol. 2026.
- Quality indicators for endoscopic retrograde cholangiopancreatography. Gastrointest Endosc. 2026.
- ACG Evidence-Based GI summary of the 2026 ERCP quality indicators.
- ASGE Journal Scan summary of the updated multi-society ERCP guidelines.
- WEO guideline on ERCP biliary cannulation and sphincterotomy techniques. 2025.
Last reviewed April 17, 2026. This update is written for clinicians and endoscopy units building a realistic ERCP quality dashboard rather than treating cannulation alone as the whole story.
